MTOR and Alzheimer disease: The metabolite exerted its anti-AD effects by upregulating AMPK, Beclin-1, and LC3 expression while suppressing mTOR and P62 levels, thereby modulating the AMPK/mTOR autophagy signaling pathway and ameliorating neurological dysfunction (Han et al., 2024).